Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07435038 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Trial sites expanded: 0 → 7 locations · Start date changed from estimate of Feb 12, 2026 to Jan 29, 2026 · Eligibility criteria expanded, about 6 words · 1 more Show 4 more changesShow less
    • Trial sites expanded: 0 → 7 locations
    • Start date changed from estimate of Feb 12, 2026 to Jan 29, 2026
    • Eligibility criteria expanded, about 6 words
    • Study description revised
  2. Study title revisedv2 See this version in full on ClinicalTrials.gov ↗
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.
Trial Details
NCT Number NCT07435038
Lead Sponsor Betta Pharmaceuticals Co., Ltd.
Conditions Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov